Avisa Diagnostics Inc. (AVBT.CN) Research

Avisa Diagnostics Inc., a clinical-stage medical device company based in Santa Fe, New Mexico, is dedicated to developing the Avisa BreathTest. This innovative drug/device biomarker technology platform is designed for the ultra-rapid identification of virulent bacterial pathogens and the subsequent monitoring of bacterial load. The system works by analyzing a patient's breath after they have inhaled or ingested Avisa's proprietary drug substrates. The company has already established clinical proof-of-concept through trials in conditions such as cystic fibrosis, tuberculosis, and community-acquired pneumonia, and is now concentrating on pivotal trials for Post-COVID-19 bronchiectasis and ventilator-associated pneumonia.

Market snapshot

Symbol
AVBT.CN
Price
$0.05
Day change
0.00%
Market cap
$87.3K
P/E ratio
-0.23x
52-week range
0.045-0.045
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Aquarius Surgical Technologies Inc. (ASTI.CN)
  • Gaia Grow Corp. (GAIA.CN)
  • Russell Investments Fallen Ange (HALO.NE)
  • Restart Life Sciences Corp. (HEAL.CN)
  • FSD Pharma Inc. (HUGE.CN)
  • Imagin Medical Inc. (IME.CN)
  • Kiaro Holdings Corp. (KO.V)
  • Wellbeing Digital Sciences Inc. (MEDI.NE)

Open Avisa Diagnostics Inc. (AVBT.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.